What Steps Should NY Biotech Take in 2018? Share Your View on Dec. 11

Xconomy New York — 

Change takes time. Particularly in the life sciences, where a single drug’s journey from idea to market can consist of more than a decade of small, yet critical steps.

For New York, then, aspirations to become a region known for its biotech industry are—and always have been—a long game in which every year and bit of progress matters. The coming year is no exception. While the region has taken steps over the years in putting several pieces in place necessary for a functional life sciences ecosystem, its status remains dwarfed by rival hubs elsewhere. 2018 is an opportunity for New York either to make more progress changing that perception, or to let its momentum slip away.

That’s why, on December 11 at the Alexandria Center for Life Science, Xconomy is zeroing in on the present in an event we’re calling “New York Biotech—The Future is Now.” We’re convening a small group of New York biotech leaders, investors, and entrepreneurs to run a town hall-style discussion with the life sciences community about the steps the region can take, right now, to gain ground on other hubs. You can get your tickets here.

The four panelists you can expect to see are:

—Vicki Sato, co-chair of the LifeSci NYC advisory council

—Barbara Dalton, VP of Venture Capital, Pfizer

—Michael Aberman, President & CEO, Quentis Therapeutics

—Eric Soller, VP of Corporate Development & Strategy, Bluerock Therapeutics

This is an interactive event that will rely, in part, on your participation—make sure to bring questions and ideas. If you register today you can still grab a discount. See you all at the Alexandria Center on Dec. 11.